Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J, Cassinat B, Porcher R, Schlageter MH, Maubec E, Pages C, Baroudjian B, Homyrda L, Boukouaci W, Tamouza R, Bagot M, Caignard A, Toubert A, Lebbé C, Moins-Teisserenc H.
Felix J, et al. Among authors: pages c.
Int Immunopharmacol. 2016 Nov;40:466-473. doi: 10.1016/j.intimp.2016.09.030. Epub 2016 Oct 8.
Int Immunopharmacol. 2016.
PMID: 27728898